Literature DB >> 17726580

Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial.

Peter C Black1, Colin P N Dinney.   

Abstract

In the majority of cases, death from bladder cancer results from metastatic disease. Understanding the closely linked mechanisms of invasion, metastasis and angiogenesis in bladder cancer has allowed us to develop new therapeutic strategies that harbor the promise of decisive improvements in patient survival. The essential link between cell based experiments and the translation of novel agents into human patients with bladder cancer is the animal model. With emphasis on the orthotopic xenograft model, this review outlines some key mechanisms relevant to angiogenesis and the development of metastasis in bladder cancer. We highlight especially pathways related to MMP-9, IL-8, VEGF and EGFR. Most commonly, expression patterns of these markers in patients have correlated to disease progression and patient survival, which has led to laboratory investigations of these markers and eventually novel targeted therapies that are translated back into the clinic by means of clinical trials. Although imperfect in their translatability into clinical efficacy, animal models remain a critical tool in bladder cancer research.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17726580     DOI: 10.1007/s10555-007-9084-9

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  38 in total

Review 1.  BCG response prediction with cytokine gene variants and bladder cancer: where we are?

Authors:  Dinesh Kumar Ahirwar; Parmeet Kaur Manchanda; Rama Devi Mittal; Hemant K Bid
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-20       Impact factor: 4.553

2.  Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma.

Authors:  Ying-Li Lin; Xiao-Qiang Liu; Wen-Ping Li; Guang Sun; Chun-Ting Zhang
Journal:  Int Urol Nephrol       Date:  2011-04-24       Impact factor: 2.370

3.  Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model.

Authors:  Cheng-Huang Shen; Jia-Jen Shee; Jin-Yi Wu; Yi-Wen Lin; Jiann-Der Wu; Yi-Wen Liu
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

4.  Interleukin-8 (IL-8) over-production and autocrine cell activation are key factors in monomethylarsonous acid [MMA(III)]-induced malignant transformation of urothelial cells.

Authors:  C Escudero-Lourdes; T Wu; J M Camarillo; A J Gandolfi
Journal:  Toxicol Appl Pharmacol       Date:  2011-10-10       Impact factor: 4.219

5.  Perioperative chemotherapy for muscle-invasive bladder cancer.

Authors:  Peter Black; Alan So
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

6.  Interleukin-20 promotes migration of bladder cancer cells through extracellular signal-regulated kinase (ERK)-mediated MMP-9 protein expression leading to nuclear factor (NF-κB) activation by inducing the up-regulation of p21(WAF1) protein expression.

Authors:  Se-Jung Lee; Seok-Cheol Cho; Eo-Jin Lee; Sangtae Kim; Soo-Bok Lee; Jung-Hyurk Lim; Yung Hyun Choi; Wun-Jae Kim; Sung-Kwon Moon
Journal:  J Biol Chem       Date:  2012-12-27       Impact factor: 5.157

Review 7.  Emerging personalized approaches for the management of advanced urothelial carcinoma.

Authors:  Che-Kai Tsao; Benjamin A Gartrell; William K Oh; Matthew D Galsky
Journal:  Expert Rev Anticancer Ther       Date:  2012-12       Impact factor: 4.512

8.  Loss of prostasin (PRSS8) in human bladder transitional cell carcinoma cell lines is associated with epithelial-mesenchymal transition (EMT).

Authors:  Li-Mei Chen; Nicole J Verity; Karl X Chai
Journal:  BMC Cancer       Date:  2009-10-22       Impact factor: 4.430

9.  Targeted therapies in the management of metastatic bladder cancer.

Authors:  Matteo Fassan; Edouard J Trabulsi; Leonard G Gomella; Raffaele Baffa
Journal:  Biologics       Date:  2007-12

10.  Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.

Authors:  M Javle; J Yu; C Garrett; A Pande; B Kuvshinoff; A Litwin; J Phelan; J Gibbs; R Iyer
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.